The S.L.I.M.M.S. Procedure for Severe Clinical Obesity
The S.L.I.M.M.S. Procedure for Severe Clinical Obesity
Assessment of Gastric Bypass combined with Vertical Sleeve Gastrectomy as primary treatment
 for patients with severe clinical obesity.

 Average percentage of total weight loss and percentage excess weight loss will be computed at
 6 months, one year and then annually. Comorbid conditions, quality of life measures, appetite
 and satiety measures and adverse events will be tracked.
BACKGROUND

 Metabolic Disease and Obesity

 Obesity is one of the most common chronic diseases in America and is strongly associated with
 additional metabolic disorders, in particular hypertension, dyslipidemia and insulin
 resistance. The combination of obesity with this cluster of metabolic disorders increases
 risk for cardiovascular disease and is widely recognized by the term Metabolic Syndrome.

 According to the Centers for Disease Control, in 2017-2018 the "prevalence of severe obesity
 among U.S. adults was 9.2%", the "age-adjusted prevalence of obesity in adults was 42.4%",
 and the prevalence of metabolic syndrome (MS) in the obese population is higher than 60%. The
 economic impact of metabolic syndrome is significant, with risk factors for MS shown to
 increase a person's annual healthcare costs by more than $2000.

 Efforts to treat obesity and obesity-associated metabolic disease currently include medical
 management and surgical intervention. Success rates with surgical interventions exceed those
 of medical management but are dependent on patients making permanent changes in eating
 behaviors.

 Commonly accepted surgical procedures have several mechanisms of action. These include
 decreased stomach volume restricting a patient's ability to eat, intestinal bypass resulting
 in significant malabsorption, and alterations in hormonal control of appetite and satiety.
 Standardized surgical procedures include Vertical Sleeve Gastrectomy (VSG), Roux-en-Y Gastric
 Bypass (GBP), Laparoscopic Gastric Banding (LB) and Biliopancreatic Diversion with Duodenal
 Switch (DS). Of these, VSG and GBP are the most commonly performed.

 VSG and GBP have been shown to result in similar weight loss, however, both procedures have a
 significant long-term failure rate.

 Key symptomatic differences between VSG and GBP

 During the initial 6-12 months after surgery, both VSG and GBP patients typically report a
 marked decrease in appetite as well as a significant restriction in volume of food that can
 be eaten before "feeling full." This period of decreased appetite and early satiety is
 commonly referred to as the "honeymoon period." After this honeymoon period, every patient's
 weight loss success becomes progressively more dependent on changes made in their eating
 habits.

 As would be expected with anatomically distinct procedures, patient symptoms begin to
 significantly differ over time. Patients that have undergone GBP, resulting in a gastric
 pouch that is less than 30cc report a more sustained feeling of restriction in the volume of
 food that can be eaten at a single meal compared to patients that have undergone VSG with a
 100-150cc residual stomach. GBP patients also report a more persistent feeling of early
 satiety than do patients after VSG. In contrast, patients that have undergone VSG, with most
 of the Ghrelin-producing region of their stomach removed, report a more persistent decrease
 in appetite compared to patients after GBP, where the production of Ghrelin appears to
 rebound.

 Key hormonal differences between VSG and GBP

 VSG results in substantial and permanent decrease in the orexigenic hormone Ghrelin. After
 GBP, rebound of Ghrelin is shown to occur within 6 to 12 months after surgery.

 GBP causes a significantly greater increase in postprandial GLP-1 and Peptide YY, possibly
 contributing to earlier satiety and improved glycemic control.

 Key differences in side effects between VSG and GBP

 A common side effect of VSG is GERD. When symptoms are severe, conversion to GBP provides
 relief.

 Dumping syndrome, a side effect of GBP, is often described as an effective negative feedback
 mechanism, helping to minimize ingestion of high glycemic index foods. Dumping is not
 typically associated with VSG.

 Considering these differences, it is reasonable to question whether a single-stage procedure
 that combines the anatomic changes of both the GBP and VSG would result in;

 1. Improved weight loss

 2. An improved quality of life

 3. Better glycemic control

 PROPOSED STUDY

 Surgical Intervention

 The S.L.I.M.M.S. Procedure, for Surgically Limit Intake and Manage Metabolic Syndrome, is a
 single-stage operation combining Roux-en-Y Gastric Bypass with Partial Gastrectomy. The
 procedure specifications are listed below,

 1. A 20 cc gastric pouch

 2. A 10 mm diameter gastro-jejunal stoma

 3. A 40 cm biliopancreatic limb (measured from the Ligament of Treitz)

 4. A 150 cm roux limb

 5. Resection of the remaining fundus and body of the stomach, maintaining the majority of
 the gastric antrum

 6. Oversewing the gastric staple lines and buttressing with omentum

 Most new procedures focus on variations of intestinal reconstruction, or involve implantation
 of artificial devices. The proposed procedure does not require implantation of an artificial
 device, nor a new method of intestinal reconstruction. It simply combines the two most common
 bariatric procedures in the world with the hope of providing cumulative benefits without
 increased risk.

 Key Technical and Anatomic Precedents

 1. When VSG results in severe and recalcitrant GERD the standard treatment is conversion to
 GBP. The final anatomic result is a patient with a gastric bypass and the majority of
 the gastric fundus and body removed. This is similar to the final anatomy of the
 procedure proposed in this study, however, the S.L.I.M.M.S. procedure will be done as a
 single operation.

 2. In several centers, resectional gastric bypass, involving a standard gastric bypass
 combined with a subtotal or total gastrectomy, is performed routinely [24-28]. Published
 reports from these centers do not demonstrate increased complications.

 Significance of this Study

 Currently accepted surgical procedures all have significant long-term failure rates or
 frequently result in substantial malnutrition. Multiple new and novel surgical procedures are
 currently being tried that focus either on simple restriction or on increasing malabsorption.
 These new procedures are not designed with the intention of providing increased, permanent
 support for the patient's behavioral changes which are so critical in the long-term success
 of all bariatric surgery. The S.L.I.M.M.S. procedure is designed with the primary goal of a
 more sustained appetite suppression and increased early satiety.

 Aims of This Study

 The specific aim of the study is to assess the safety and efficacy of the S.L.I.M.M.S.
 Procedure as a stand-alone, single-stage bariatric operation.

 METHODS

 Trial Protocol

 1. Patient Recruitment

 a. Recruitment into the study will be achieved by a physician awareness campaign using
 direct mail. An Internet awareness campaign will target potential patients.
 Announcements will include description of planned procedure, aim of study and
 experimental nature of the S.L.I.M.M.S. Procedure.

 2. Patient Education

 a. Patient Education consisting of i. Detailed Consultation ii. Patient Education Packet
 iii. Written Examination iv. Education on pre- and post-operative dietary protocols v.
 Mandatory Dietary Rebuild counselling program vi. Permanent Surgical Weight Loss book
 provided vii. DietaryRebuild™ book provided viii. Exercise Instructions ix. Nutrition
 Supplementation Instructions

 3. Patient Enrolment

 a. Enrolment into the study will be proceeded by patient education including a detailed
 discussion of the nature of this clinical trial. A detailed consent will also be
 provided.

 4. Pre-trial Assessment

 1. Initial clinical assessment will include a detailed dietary history and a review
 for co-morbidities of obesity.

 2. Assessment of nutrition knowledge and quality of life will be obtained using the
 General Nutrition Knowledge Questionnaire, the Bariatric Quality of Life Index and
 the SF-36/Rand.

 3. Clinical assessment will include various weight parameters and measurement of serum
 glucose, hemoglobin A1c, lipids, vitamin levels, iron, ferritin, RBC folate,
 complete blood count, comprehensive metabolic profile, and abdominal ultrasound.

 5. Surgery: S.L.I.M.M.S. Procedure

 6. Patient Support

 1. In-clinic follow up

 2. Support groups offered

 3. Telephone-based group counselling sessions

 7. Post-operative Assessment

 1. Weight Parameters measured at 6 months, 12 months and annually

 2. Laboratory assessment will include serum glucose, hemoglobin A1c, lipids, vitamin
 levels, iron, ferritin, RBC folate, complete blood count, comprehensive metabolic
 profile and lipid profile at 6 months, 12 months and annually thereafter

 3. Quality of life measure at 1, 12 and 24 months; Bariatric Quality of Life Index and
 SF-36/Rand
Inclusion Criteria:

 1. Be between 18 and 65 years of age

 2. Have a body mass index of equal to or above 35 kgs per m2

 3. Have identifiable obesity-related comorbidity; medical, physical or psycho-social

 4. A history of attempts at weight reduction within the past five-year period

 5. Ability to understand the non-surgical and surgical options for weight loss

 6. Understand the behavioral changes needed to maximize surgical weight loss success

 7. Agree to comply with recommended follow-up clinical assessments

 8. Agree to comply with lifelong nutritional supplementation

 Exclusion Criteria:

 1. Lack of ability to understand weight loss options and requirements for long-term
 success with surgery

 2. Inability to understand and accept the risks and potential benefits

 3. Inability to understand and agree to the compliance requirements of the study

 4. Prior gastric surgery including all forms of bariatric surgical or endoscopic
 procedures

 5. A history of previous abdominal surgery which precludes gastric bypass

 6. Medical contra-indications to bariatric surgery

 7. Dementia, active psychosis, unstable psychiatric disease

 8. Concurrent experimental drug use

 9. Pregnancy or intending to conceive within 12 months or current breast-feeding

 10. Recreational drug use or excessive alcohol intake

 11. Use of drugs known to affect body composition

 12. Use of cytotoxic drugs